Literature DB >> 3107871

Binding and antibody blocking effects of intravenous IgG preparation on peripheral blood cells.

R M Minchinton, K McGrath.   

Abstract

The mode of action of high dose intravenous gammaglobulin (IVGG) in idiopathic thrombocytopenic purpura (ITP) is controversial. This study used immunofluorescence techniques to investigate the possibility that IVGG binds to peripheral blood cells and that such binding blocks attachment of cell specific autoantibodies. IVGG bound to platelets, neutrophils, monocytes and lymphocytes. Erythrocytes appeared to bind only anti-A and anti-B present in the IVGG. Multimeric and monomeric fractions of IVGG also bound to these cells. However, F(ab')2 fragments of the IVGG reacted only weakly with platelets, neutrophils, monocytes and lymphocytes. Binding of IVGG to platelets and neutrophils did not prevent opsonization of these cells by monoclonal antibodies with specificities corresponding to those previously ascribed to platelet and neutrophil autoantibodies. This suggests that IVGG does not act by blocking attachment of autoantibodies to platelets in ITP.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3107871     DOI: 10.1111/j.1365-2257.1987.tb01381.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  4 in total

1.  Cellular changes during the infusion of high dose intravenous immunoglobulin.

Authors:  A C Newland; M G Macey; P A Veys
Journal:  Blut       Date:  1989-07

Review 2.  Mechanism of action of intravenous immunoglobulin in immune-mediated cytopenias.

Authors:  H I Atrah; R J Davidson
Journal:  J Clin Pathol       Date:  1988-12       Impact factor: 3.411

3.  Neutropenia following intravenous immunoglobulin.

Authors:  P A Veys; M G Macey; C M Owens; A C Newland
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-25

4.  Immune thrombocytopenia and Fc receptor-mediated phagocyte function.

Authors:  A C Newland; M G Macey
Journal:  Ann Hematol       Date:  1994-08       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.